Human PBMC Model Development Service

Human PBMC models serve as a critical preclinical platform for recapitulating human immune responses, enabling the evaluation of immunotherapies and the study of immune-related adverse events such as CRS. Creative Biolabs' Human PBMC Model Development Service is tailored for CRS management. Leveraging advanced humanized mouse systems and robust engraftment techniques, we provide a physiologically relevant human immune context for accurate risk assessment and therapeutic screening. We offer clients a validated, customizable model to investigate CRS mechanisms, predict immunotoxicity, and support the development of safer and more effective immunomodulatory strategies.

Introduction

The human PBMC model is a humanized mouse model featuring a reconstituted human immune system through the engraftment of human PBMC cells into immunodeficient mice. This platform serves as a valuable preclinical tool for recapitulating human immune responses, enabling the evaluation of immunotherapeutic strategies, drug toxicity testing, and mechanistic studies of immune-related diseases. More importantly, the human PBMC model provides a reliable preclinical basis for modeling CRS pathogenesis, assessing immunotherapy-related risks, and developing targeted intervention strategies.

Fig.1 Engraftment of human PBMC-derived HSCs in immunodeficient mice.¹

Human PBMC Model Development Service at Creative Biolabs

Creative Biolabs' Human PBMC Model Development Service provides a physiologically relevant platform for predictive assessment of cytokine release syndrome risk. Utilizing primary human immune cells, we deliver quantitative, dose-responsive profiling of proinflammatory cytokine release to support your immunotherapeutic safety evaluation. Our human-relevant approach enables accurate risk stratification, informs clinical dosing strategies, and facilitates comparative candidate selection.

What We Can Offer

We deliver a comprehensive solution for CRS assessment, offering predictive, human-relevant models and deep mechanistic insights to guide your critical safety decisions.

Our Service Process

Required starting materials:

• Test Agent: Soluble monoclonal antibodies, engineered cell therapies, or other protein therapeutics.
• Desired Cytokine Panel: Specification of primary and optional secondary proinflammatory cytokines for quantification.
• Target Cell Line (if required): Relevant tumor cell lines.

Key Steps Involved:

Final Deliverables:

• Raw cytokine concentration data.
• Statistical Analysis.

Key Advantages

• Predictive Assay Customization: We provide bespoke assay configurations, including soluble, immobilized, and co-culture formats, tailored to the specific mechanism of action of your biologic or cell therapy. This customization ensures high predictive accuracy for assessing clinical immunogenicity risk.
• Comprehensive Cytokine Profiling: Utilizing state-of-the-art multiplex platforms, we deliver precise quantification of the complete spectrum of CRS-relevant cytokines at picogram-level sensitivity, defining the definitive cytokine signature of your candidate.
• Accelerated Lead De-risking: Our high-throughput screening systems enable rapid parallel evaluation and comparative analysis of multiple candidate molecules, streamlining the selection process and reducing both timeline and resource investment during critical development stages.

FAQ

Why Choose Us?

We offer tailored human PBMC model development and immunogenicity testing services, specifically designed to support the assessment of CRS. By choosing our service, you gain a trusted partner committed to providing physiologically relevant insights and robust data to help de-risk your therapeutic programs.

Customer Reviews

"The ability to quickly pair the in vivo PBMC efficacy data with the in vitro CRS risk prediction assay was invaluable. This integrated safety checkpoint, utilizing human PBMCs, facilitated our application strategy and provided crucial data for our safety filing."— A. K. Rob***on, Head of Translational Sciences, Cell Therapy Institute.

"Using Creative Biolabs' Human PBMC Model Development Service in our research has significantly improved the reproducibility of our anti-PD-1 efficacy studies. The technical consistency across donors and the robust flow cytometry data on TILs allowed us to confidently select our lead candidate."— Dr. M. Smi***h, Research Director, BioPharma R&D.

How to contact us?

To explore how a scientific partnership can advance your immuno-oncology program toward the clinic, contact our specialists to initiate a customized project discussion.

Reference

1. Serr, Isabelle et al. "Advances in Human Immune System Mouse Models for Personalized Treg-Based Immunotherapies." Frontiers in immunology vol. 12 643544. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2021.643544.